CIRCULOGENE is the leader in molecular cancer diagnostics. By applying our proprietary cell-free DNA recovery and enrichment technology, CIRCULOGENE is the first and only company to use minimal-volumes of blood to monitor tumors and the first company to develop a next-generation sequencing method to provide full genomic load analysis. CIRCULOGENE is founded and operated by leaders and scientists from the diagnostics industry.
Mike Mullen, Co-Founder, President and CEO
Mike Mullen has more than 25 years in executive and financial leadership positions. He was most recently the President and CEO of Atherotech Diagnostics. Prior to Atherotech, Mike held various financial positions with several companies, including Ernst & Young. Mike holds both medical technology and accounting degrees and was the Southeast recipient of the Ernst & Young Entrepreneur of the Year award in 2014.
Chen-Hsiung Yeh, Ph.D., Co-Founder, Chief Scientific Officer
Dr. Chen-Hsiung Yeh has over 20 years’ experience in drug discovery and molecular diagnostics in the biotech, pharmaceutical and diagnostics industries. He has held leadership roles at Pfizer, Response Genetics, Quest Diagnostics and Atherotech Diagnostics. Chen is a pioneer in the liquid biopsy field and the inventor of CIRCULOGENE’s core technology.
Scott Rezek, Co-Founder, Chief Marketing Officer
Scott Rezek has managed global project teams, national sales forces, marketing and technology teams, and service organizations. His most recent position was Chief Commercial Officer at Atherotech Diagnostics. Prior to that, Scott was Director of Marketing/Global E-Business at Invitrogen. He holds a master’s degree and a bachelor’s degree in marketing.
Anthony L. Schmidt, M.D., F.A.C.P., Lab Director
Board certified in anatomical and clinical pathology, and in hematology and transfusion medicine, Dr. Schmidt’s expertise in advanced diagnostics is focused on achieving improved patient outcomes through precision testing and clinical support. Dr. Schmidt earned his bachelor’s degree in chemistry at Florida Atlantic University and his doctor of medicine degree from the University of Miami School of Medicine in Miami, Florida. After completing his pathology residency at Dartmouth Hitchcock Medical Center in Lebanon, New Hampshire, Dr. Schmidt received fellowship training in transfusion medicine and hematopathology from the University of Iowa Hospitals and Clinics in Iowa City, Iowa.